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Abstract
Runx1 is an important haematopoietic transcription factor as stressed by its involve-
ment in a number of haematological malignancies. Furthermore, it is a key regulator of
the emergence of the first haematopoietic stem cells (HSCs) during development. The
transcription factor Gata3 has also been linked to haematological disease and was
shown to promote HSC production in the embryo by inducing the secretion of impor-
tant niche factors. Both proteins are expressed in several different cell types within the
aorta-gonads-mesonephros (AGM) region, in which the first HSCs are generated;
however, a direct interaction between these two key transcription factors in the context
of embryonic HSC production has not formally been demonstrated. In this current
study, we have detected co-localisation of Runx1 and Gata3 in rare sub-aortic mesen-
chymal cells in the AGM. Furthermore, the expression of Runx1 is reduced in
Gata3−/− embryos, which also display a shift in HSC emergence. Using an AGM-
derived cell line as a model for the stromal microenvironment in the AGM and per-
forming ChIP-Seq and ChIP-on-chip experiments, we demonstrate that Runx1,
together with other key niche factors, is a direct target gene of Gata3. In addition, we
can pinpoint Gata3 binding to the Runx1 locus at specific enhancer elements which are
active in the microenvironment. These results reveal a direct interaction between Gata3
and Runx1 in the niche that supports embryonic HSCs and highlight a dual role for
Runx1 in driving the transdifferentiation of haemogenic endothelial cells into HSCs as
well as in the stromal cells that support this process.
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1 | INTRODUCTION
Haematopoietic stem cells (HSCs) are clinically highly rele-
vant cells that have been widely used for cell replacement
therapies; however, their use for transplants is limited by the
Abbreviations: Ack9, acetylated histone H3 Lysine 9; AGM, aorta-gonads-
mesonephros; Ao, dorsal aorta; ChIP, chromatin immunoprecipitation;
DHS, DNase I hypersensitive site; E, embryonic day; HSC, haematopoietic
stem cell; IAHC, intra-aortic haematopoietic cluster; ITD, internal tandem
duplication; PSC, pluripotent stem cell; SNS, sympathetic nervous system.
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availability of compatible donors. Considerable effort is
therefore being invested into the development of protocols
for the derivation of HSCs from pluripotent stem cells
(PSCs) in vitro as these could be derived from the patient's
own cells. PSC differentiation into transplantable HSCs has
proven to be challenging, although significant progress has
been made in recent years.1,2 One important component for
success in these endeavours is a detailed understanding of
how the embryo generates HSCs during development
in vivo. The first and most robust production of HSCs
occurs in the aorta-gonads-mesonephros (AGM) region
starting from E10.5.3–5 The generation of HSCs involves the
transdifferentiation of specialised haemogenic endothelial
cells into blood cells in a process termed endothelial-to-
haematopoietic transition, which is regulated by key tran-
scription factors such as Runx1, Gata2, and Gfi1 and major
signalling pathways, such as Notch and Bmp, which interact
in a finely-tuned manner (recently reviewed in6).
This process is also embedded in and regulated by the
local microenvironment, which in the AGM appears to be
especially supportive to the generation of HSCs (reviewed
in7). The AGM haematopoietic niche is very dynamic and
includes contributions from tissues that develop in its vicin-
ity at the time of HSC emergence, such as the sympathetic
nervous system (SNS)8 and the gut.9 Furthermore, the AGM
was demonstrated to contain mesenchymal stem/stromal cell
activity,10 and the ventral sub-aortic mesenchyme is a rich
source of many haematopoiesis-regulatory factors.11–14 This
mesenchymal population appears to be very heterogeneous,
and very little is currently known about its developmental
origins, whether it is maintained by a local stem cell popula-
tion and where the key HSC niche cells are located.
We demonstrate here that two important haematopoietic
transcription factors, Gata3 and Runx1, both of which also
perform important roles in adult haematopoietic lineages,15,16
are co-expressed in the sub-aortic mesenchyme of the AGM
and that their interaction may regulate the timing of HSC
emergence. Furthermore, using AGM-derived stromal cell
lines as a model,11,13,17 we demonstrate that Runx1 as well as
other important haematopoietic factors such as Kit and Cxcl12
are direct targets of Gata3. This highlights that some key
HSC regulators such as Runx1 can perform cell-intrinsic roles
and at the same time function within the HSC niche.
2 | EXPERIMENTAL PROCEDURES
2.1 | Mice
Wild-type C57BL/6, Gata3 knockout,18 Gata3-LacZ
knockin,19 Gata3-GFP knockin,20 or Runx1-LacZ knockin21
mice were mated for embryo generation. The day of plug
detection is designated as day 0. All mice were housed
according to institute regulations, and procedures were car-
ried out in compliance with UK Home Office licenses.
2.2 | Long-term transplantations
Dissected AGMs were dissociated with 0.125% collagenase
and single cell suspensions injected into irradiated (split dose
of 9.5 Gy γ-irradiation) recipient mice together with 200,000
spleen helper cells. Donor contribution was measured at
1 and 4 months post-transplantation by flow cytometry,
using antibodies specific to the CD45.1 and CD45.2
isoforms. Mice were considered positive for repopulation if
donor chimerism exceeded 5%.
2.3 | Immunohistochemistry,
immunocytochemistry and X-gal staining
Embryos were fixed with 2% paraformaldehyde at 4C, equili-
brated overnight at 4C in 30% sucrose and then snap-frozen in
Tissue Tek (Sakura Finetek). Ten micrometre cryosections
were prepared and stained with anti-GFP (chicken; Life Tech-
nologies), anti-Runx1 (rabbit; Abcam), anti-CD34 (FITC),
anti-chicken-Alexa647 (Millipore), anti-rabbit-Alexa555, anti-
Kit (goat; R&D Systems), and anti-goat-Alexa488 before
mounting in DAPI-containing Vectashield (Vectorlabs).
UG26-1B6 cells grown on microscope slides were stained with
anti-Gata3 (rat; Absea), anti-rat-biotin (BD Biosciences), and
Streptavidin-Cy5 (Jackson Immunoresearch) before mounting
in DAPI-containing Vectashield. X-gal staining of Gata3+/lz
and Runx1+/lz embryos was carried out as described previ-
ously.22 Cryosections were prepared and counterstained with
Neutral Red. Brightfield images were acquired with a Zeiss
AxioSkop2 Wide-Field Microscope and fluorescent images
with a Widefield Zeiss Observer and analysed using Zen
software.
2.4 | Gene expression
Tissues and cells were dissociated in Trizol (Life Technolo-
gies) and RNA isolated and DNAse-treated according to
manufacturer's instructions. First strand cDNA was gener-
ated with Superscript II (Invitrogen) and conventional RT-
PCR performed with primers for Gata3 (forward: CGAAA
CCGGAAGATGTCTAGC; reverse: AGGAACTCTTCGC
ACACTTGG), Runx1 (forward: CGGAGGGAAACTGTGA
ATGC; reverse: CCCAAAGCTGTAGCTGTCTC), Cxcl12
(forward: TTTCACTCTCGGTCCACCTC, reverse: TAATT
TCGGGTCAATGCACA), and Actb (forward: CCTGAACC
CTAAGGCCAACCG, reverse: GCTCATAGCTCTTCTC
CAGGG).
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2.5 | Cell culture
The UG26-1B6 and KH23 stromal cell lines were grown at
33C in medium containing 50% Myelocult M5300 (Stem
Cell Technologies), 35% α-MEM (Invitrogen), 15% fetal
calf serum (Sigma Aldrich), 0.5% penicillin–streptomycin
(Sigma Aldrich), and 10 μM β-mercaptoethanol.
2.6 | ChIP-qPCR and ChIP-Seq
Chromatin immunoprecipitation (ChIP) was performed using
an anti-Gata3 antibody (rat, Absea or goat, Santa Cruz), an
anti-H3K9Ac antibody (rabbit, Millipore) and their respective
IgG controls. ChIP material was analysed by qPCR using the
following primers: Mafk (forward: CTCGTGTTGTCTTTC
CGCAC, reverse: CGACCTTGGGATGTAGCCAA); Tcf3
(forward: GGAACTATCTTCCTACGCGGC, reverse: TAA
TGGTCCTTCCCGCTTGC); Ccdc34 (forward: TGATGTC
AGCACTCTGCCTC, reverse: TTGTGCCAGGACAAGCA
GAT); Cd28 (forward: TCTTTCCATTGCTTTGCGGC,
reverse: TGGCCACTCACTATGCATCT); Klf6 (forward:
ATCTGCAGCTGCTGGACAAC, reverse: TGCATGAGTC
AGCGTCTTCA); Lmo7 (forward: GGTGGCAGTCTTGGA
AGTCA, reverse: TGAGTAACCAGCGACACACC); Cxcl12
(forward: ATGTGCGCCCTGCAGATATT, reverse: AGCGT
GAGTCATCGACTTGG); Runx1 (forward: AGCAGCACC
GAATGAGTCAA, reverse:CGTATGCTGGGCCTTTCCTC);
Runx1 + 23 (forward: CGAAAAATAAACCGGCAGTTGA,
reverse: CAAGCTGCCCACGTTATCAGT); Runx1 + 110
(forward: CCTTTACATCTCCTCAATCATTGCT, reverse:
TCCAAATGCCCCCAGTCA); Runx1 + 3 (forward: ACCAC
AGCCTGCCACTCCTA, reverse: AGGGAGCACAGGCCAT
AAATTA); Gapdh (forwards: CAAGGCTGTGGGCAAGGT,
reverse: TCACCACCTTCTTGATGTCATCA). ChIP-Seq exp-
eriments were carried out as described previously.23 Samples
were amplified, sequenced on an Illumina 2GGenome Analyzer
and analysed as described previously.24 The sequencing data
have been submitted to the NCBI Sequence Read Archive and
are accessible via accession number PRJNA557177.
2.7 | Luciferase assay
The Runx1 + 23 and + 171 elements were inserted down-
stream of the luciferase gene and the SV40 promoter in the
pGL3 vector. pGL3 vector without an enhancer element
(and just the SV40 promoter) was used as a negative control.
UG26-1B6 cells were co-transfected with the test vectors
and the pRL-TK control plasmid and luciferase activity
determined as described previously.25
3 | RESULTS AND DISCUSSION
Our group previously reported a defect in HSC production in
the Gata3−/− E11 AGM region, which was rescuable by sup-
plying the Gata3-deficient embryos with an external source of
catecholamines.8 These results suggested that Gata3 regulates
AGM HSC numbers primarily via controlling catecholamine
synthesis from the co-developing SNS. When we repeated the
rescue experiments with E10.5 embryos, a time point when
mature HSC numbers in the AGM are very low and virtually
undetectable in direct transplantations,5,26 we were surprised to
find repopulation activity specifically in Gata3-null E10.5
AGMs (Table 1). As expected, no recipients displayed any chi-
merism with injected E10.5 wild-type or Gata3+/− AGMs,
while half of the recipients of E10.5 Gata3−/− AGM cells
exhibited robust donor contribution (Table 1). These results
imply that in catecholamine-rescued embryos Gata3 deficiency
induces a temporal shift in the appearance of HSCs which is
SNS-independent. Such a shift towards an earlier appearance
of HSCs in the AGM has previously been observed in Runx1
haploinsufficient embryos.27 Intriguingly, we detected a sub-
stantial reduction in Runx1 expression levels (64% of wild-
type) in Gata3−/− AGMs (Figure 1a) as reported previously.8
This may indicate that Runx1 expression in the AGM is at least
partially dependent on Gata3, and that the reduced dose of
Runx1 in Gata3−/− AGMs may be responsible for the earlier
appearance of HSCs.
Previous analyses have localised Runx1 expression to intra-
aortic clusters, aortic endothelial cells, and sub-aortic
mesenchyme,13,21 while Gata3 is not expressed in intra-aortic
clusters and only in a small subset of aortic endothelial and
sub-aortic mesenchymal cells.8 The most substantial overlap
between these two transcription factors appears to be in the
sub-aortic mesenchyme (Figure 1b,c), where we detected co-
expression within the same cells (Figure 1d).
To determine whether Runx1 is indeed a direct target of
Gata3, we performed ChIP with an antibody to Gata3
followed by massively parallel sequencing (ChIP-Seq). As
this technique requires large cell numbers that would be
TABLE 1 HSC activity in AGMs from catecholamine-treated
E10.5 embryos
Genotype
No. of mice repopulated/
total transplanted
Percentage
chimerism
Gata3+/+ 0/2 0
Gata3+/− 0/4 0
Gata3−/− 2/4 60, 13
Note: AGMs from E10.5 embryos (35–39 somite pairs) were transplanted at one
embryo equivalent directly into irradiated adult recipients and chimerism
determined after 4 months. Results are from two independent experiments.
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impossible to obtain from sorted primary sub-aortic mesen-
chymal cells, only a subset of which co-expresses Gata3 and
Runx1, we made use of an AGM-derived stromal cell line,
UG26-1B6, which has been well characterised and used as a
model for AGM haematopoiesis-supportive stroma.11,13,17
Most importantly, it expresses both Gata3 and Runx1, as
well as Cxcl12, a chemokine that was identified as one of
the key factors by which niche cells regulate HSC
behaviour28–30 (Figure 2a,b). Runx1 was indeed identified as
one of the most significant Gata3 target genes (Table 2,
Figure 2c), and the list of target genes also included Cxcl12.
Several of the identified Gata3 targets in Table 2 have also
been identified as target genes of multiple key haematopoietic
transcription factors,24 and we confirmed some of these as top
Gata3 targets by ChIP-qPCR (Figure 2d–k). An antibody
against acetylated histone H3 Lysine 9 (Ack9) was also
included to confirm accessibility and activity of the identified
sites. While Gata3 clearly occupied all of these sites, we could
only detect enrichment for Ack9 at the loci for Mafk and Tcf3
(Figure 2d,e). The absence of the Ack9 modification at the
other sites (Figure 2f–k) could either mean that Gata3 acts as a
repressor of these genes or that it can bind to closed chromatin
prior to activation, suggesting that it has pioneer factor activity.
Many well-known reprogramming factors such as Oct4, Sox2
and Klf4 have been described to possess pioneer factor activ-
ity.31 It is therefore intriguing to note that Gata3 was recently
described as a reprogramming factor required for the conver-
sion of mouse fibroblasts into trophoblast stem cells.32,33
Whether Gata3 really possesses pioneer factor activity and
whether this is important for its function in driving major cell
fate decisions during normal development34 is an exciting pos-
sibility that will require further investigations.
To identify further Gata3 target genes, especially ones that
have been linked to haematopoietic processes, we also per-
formed a ChIP-on-chip assay, which involved hybridising
Gata3-bound genomic fragments pulled down with the same
Gata3 antibody to a customised microarray chip that contained
probes of gene loci linked to haematopoiesis (data no shown).
FIGURE 1 Gata3 and Runx1
co-localise in the sub-aortic
mesenchyme. (a) Runx1 expression by
qPCR in AGMs from E11 Gata3+/+
and Gata3−/− embryos. (b) Gata3
expression as detected by X-gal
staining in cryosections from E11
Gata3+/lz embryos counterstained with
Neutral Red. (c) Runx1 expression as
detected by X-gal staining in
cryosections from E11 Runx1+/lz
embryos. (d) Immunohistochemistry
of a cryosection from a Gata3+/GFP
E11 embryo with antibodies to GFP
(red), Runx1 (white), CD34 (green),
and counterstained with DAPI.
Smaller panels show a virtual zoom of
the region defined by the red box.
Asterisks highlight Runx1+ intra-
aortic clusters; arrow points to Runx1
and Gata3 co-localisation in the sub-
aortic mesenchyme
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FIGURE 2 Runx1 is a direct target gene of Gata3 in AGM-derived UG26-1B6 stromal cells. (a) Expression of Gata3, Runx1, Cxcl12, and
Actb in UG26-1B6 cells measured by RT-PCR. (b) UG26-1B6 cells stained with an antibody to Gata3 (red) and counterstained with DAPI (blue).
(c) UCSC Genome browser depiction of the Gata3 binding peak at the +171 enhancer in the Runx1 locus as measured by ChIP-Seq. (d–k) ChIP-
qPCR for the indicated gene loci with UG26-1B6 cell DNA immunoprecipitated with anti-H3K9Ac (“Ack9”) and anti-Gata3 antibodies with their
respective controls (rabbit IgG [“IgGR”] and goat IgG [“IgGG”]). (l) Immunohistochemistry for Kit (green) on E11 wild-type embryo cryosections
counterstained with DAPI. (m–p) ChIP-qPCR for the indicated Runx1 enhancer elements with UG26-1B6 cell DNA immunoprecipitated with anti-
H3K9Ac (“Ack9”) and anti-Gata3 antibodies with their respective controls (rabbit IgG [“IgGR”] and goat IgG [“IgGG”]). (q) Replicate Luciferase
assays on UG26-1B6 cells transfected with pGL3 vector without any enhancer elements (negative control) or containing the Runx1 + 23 and + 171
enhancers. Ao, dorsal aorta; IAHC, intra-aortic haematopoietic cluster
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Amongst the significant targets were several hits for Kit, which
in addition to its strong expression in intra-aortic clusters is also
widely expressed in the sub-aortic mesenchyme (Figure 2l),
and Pdgfra, a well-known mesenchymal gene. Most impor-
tantly, Runx1 was once again confirmed as a direct Gata3
target gene.
The genetic elements that regulate the tissue-specific
expression of Runx1 have been well characterised (recently
reviewed in35). Runx1 is under the control of two different
promoters, which result in the generation of two different
isoforms. The distal promoter (P1) is activated in foetal liver
and adult haematopoiesis, while the proximal promoter
(P2) is active during the early stages of HSC generation from
haemogenic endothelial cells.36,37 In addition to the two pro-
moters, tissue-specific expression of Runx1 is also regulated
through a number of enhancers, the best studied of which is
the +23 enhancer, which targets Runx1 expression to
haemogenic endothelial cells and HSPCs.25,38,39 To gain
insight into the mechanisms through which Gata3 regulates
Runx1 expression, we analysed its occupancy on different
Runx1 enhancer elements in UG26-1B6 stromal cells. It
showed by far the strongest enrichment at the +171
enhancer with some weak occupancy at the +3 enhancer and
no binding at the +23 or + 110 enhancers (Figure 2c,m–p).
Luciferase assays confirmed that the +171 enhancer is active
in UG26-1B6 cells, albeit not as strongly as the +23
enhancer (Figure 2q). The activity of the +171 enhancer is
comparatively unexplored (compared, for example, with the
+23 enhancer), although transient transgenics have shown it
to be active in the mouse AGM region (Marella de Bruijn,
personal communication). Of note, the human equivalent
(+43 kb from the second promoter) of the mouse +171 ele-
ment was recently shown to contain a DNaseI hypersensitive
site (DHS) that is specific to acute myeloid leukaemia sam-
ples with internal tandem duplications in the transmembrane
domain of FLT3 (FLT3-ITD).40 Furthermore, the human
+43 FLT3-ITD-specific DHS contains two conserved
GATA sites.
Our results have clearly shown that there is an interaction
between Gata3 and Runx1 in the embryonic haematopoietic
stromal microenvironment and that Runx1 is a direct target
of Gata3 in this context. Whether it is this interaction that
can explain the early appearance of HSCs in catecholamine-
rescued Gata3−/− AGMs requires further investigation. We
attempted to knockdown Gata3 expression in UG26-1B6
cells in order to assess how this affected Runx1 expression
and the ability of these stromal cells to support
haematopoietic cells in co-cultures13; however, the knock-
down of Gata3 had a negative impact on the viability and/or
growth of these cells, which made it impossible to maintain
low Gata3 levels during subsequent culture steps (data not
shown).
It has, however, been previously demonstrated that a half
dose of Runx1 results in a more supportive microenviron-
ment through co-culture experiments with stromal cell lines
derived from Runx1+/+, Runx1+/− and Runx1−/− AGMs.13
We checked whether Gata3 binds to similar targets in the
Runx1+/− KH23 AGM-derived cell line by ChIP-qPCR and
confirmed enrichment at the Klf6, Lmo7, Cxcl12, and Runx1
locus, although these loci appear to be more accessible in
this cell line (Figure 3a–d).
In summary, we have demonstrated that Runx1 is a target
gene of Gata3 in the HSPC-supportive stromal compartment
of the AGM region using two different AGM-derived stro-
mal cell lines as in vitro models. Gata3 appears to bind pref-
erentially to the +171 enhancer element of Runx1.
Furthermore, the transplantation results as well as the results
with the Runx1+/− KH23 stromal cell line suggest that the
interaction between these two transcription factors may regu-
late the supportive capacity of the AGM niche, with the
exact dose of Runx1 being a critical factor. Interestingly,
Gata3 and Runx1 are also both expressed in the haemogenic
endothelium of the dorsal aorta.38 Whether there is also a
direct interplay between these two factors in the haemogenic
endothelium and what the nature of this interaction is, is cur-
rently under investigation, although unpublished sequencing
data from our lab was unable to detect enrichment of Runx1
expression in Gata3-positive aortic endothelial cells (Zaidan
et al., manuscript in preparation).
TABLE 2 Most significant Gata3 target genes in UG26-1B6
AGM-derived stromal cells as identified by ChIP-Seq analysis
1.00E-15 1.00E-12 1.00E-09
Ccdc34 Adamts14 Cd28
Spint1 Ptpru Atf3
Polr3g1 Hscb Ccrn41
Mafk Crybb1 Ankrd6
Ano2 Nsmce1 Osbp19
Hpgd Shank2 Lactb
Lsm4 Tln2 Lep
Ddx39 Rasgrf1 Fam188b
Tcf3 Adamts16 Cxcl12
Ccdc6 Scd2 Cradd
Klf6 Ebf1
Gtf2h2 Xpo4
Nid2 Cdh18
Lmo7 Ano6
Ank Prkd3
Runx1
BC003965
Note: Genes in bold were confirmed by ChIP-qPCR.
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